title: Low molecular weight fucoidan prevents intimal hyperplasia in rat injured thoracic aorta through the modulation of matrix metalloproteinase-2 expression.
abstract: The therapeutic potential of low molecular-weight fucoidan (LMWF), a sulfated polysaccharide extracted from brown seaweed was investigated on vascular smooth muscle cell (VSMC) and human vascular endothelial cell (HUV-EC-C) proliferation and migration in vitro and in a rat model of intimal hyperplasia. Sprague-Dawley rats were subjected to balloon injury in the thoracic aorta followed by two weeks' treatment with either LMWF (5mg/kg/day) or vehicle. Morphological analysis and proliferating cell nuclear antigen immunostaining at day 14 indicated that LMWF prevented intimal hyperplasia in rat thoracic aorta as compared with vehicle (neo-intima area, 3±0.50mm(2) versus 5±0.30mm(2), P<0.01). In situ zymography showed that LMWF significantly decreased the activity of matrix metalloproteinase (MMP)-2 in the neo-intima compared to vehicle. The in vitro study demonstrated that 10μg/ml LMWF increased HUV-EC-C migration by 45±5% but reduced VSMC migration by 40±3%. LMWF also increased MMP-2 mRNA expression in HUV-EC-Cs and reduced it in VSMCs. MMP-2 level in the conditioned medium from cells incubated with 10μg/ml LMWF was 5.4-fold higher in HUV-EC-Cs, but 6-fold lower in VSMCs than in untreated control cells. Furthermore, decreasing MMP-2 expression in HUV-EC-Cs or VSMCs by RNA interference resulted in reduced LMWF-induced effects on cell migration. In conclusion, LMWF increased HUV-EC-C migration and decreased VSMC migration in vitro. In vivo, this natural compound reduced the intimal hyperplasia in the rat aortic wall after balloon injury. Therefore, LMWF could be of interest for the prevention of intimal hyperplasia.
authors.affiliation: INSERM U698, Bio-ingénierie Cardiovasculaire, Université Paris 13, France.
authors.forename: Hanna
authors.initials: H
authors.lastname: Hlawaty
authors.forename: Nadine
authors.initials: N
authors.lastname: Suffee
authors.forename: Angela
authors.initials: A
authors.lastname: Sutton
authors.forename: Olivier
authors.initials: O
authors.lastname: Oudar
authors.forename: Oualid
authors.initials: O
authors.lastname: Haddad
authors.forename: Veronique
authors.initials: V
authors.lastname: Ollivier
authors.forename: Christelle
authors.initials: C
authors.lastname: Laguillier-Morizot
authors.forename: Liliane
authors.initials: L
authors.lastname: Gattegno
authors.forename: Didier
authors.initials: D
authors.lastname: Letourneur
authors.forename: Nathalie
authors.initials: N
authors.lastname: Charnaux
mesh_terms: D000818:Animals; D001013:Aorta, Thoracic / Q000293:injuries* / Q000473:pathology; D002465:Cell Movement; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D006801:Humans; D006965:Hyperplasia / Q000517:prevention & control*; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000235:genetics / Q000378:metabolism*; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000502:physiology; D011134:Polysaccharides / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017539:Tunica Intima / Q000166:cytology / Q000473:pathology
chemical_list: D011134:Polysaccharides; C007789:fucoidan; D020778:Matrix Metalloproteinase 2